At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
RXRX Recursion Pharmaceuticals, Inc.
Trading 02-10 11:53:40 EST
4.06
+0.08
+1.88%
High4.09Low3.93Vol4.58M
Open4.01D1 Closing3.98Amplitude3.89%
Mkt Cap2.11BTradable Cap1.68BTotal Shares519.84M
T/O18.46MT/O Rate1.10%Tradable Shares415.00M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

11 Stocks That Have Cratered and Look Like Buys -- Barrons.com
Dow Jones  ·  02-10 03:22
11 Stocks That Have Cratered and Look Like Buys -- Barrons.com
Nvidia Concept Stocks Rally. Applied Digital And CoreWeave Up 7%; Nebius Up 6%; Nvidia And Core Scientific Up 3%; WeRide Up 2%
Tiger Newspress  ·  02-09 23:03
Nvidia Concept Stocks Rally. Applied Digital And CoreWeave Up 7%; Nebius Up 6%; Nvidia And Core Scientific Up 3%; WeRide Up 2%
Is Recursion Pharmaceuticals (RXRX) Pricing Reflect Its Steep Share Price Declines And DCF Outlook
Simply Wall St.  ·  02-09 07:12
Is Recursion Pharmaceuticals (RXRX) Pricing Reflect Its Steep Share Price Declines And DCF Outlook
Recursion Pharmaceuticals Director Christopher Gibson Reports Sale of Common Shares
Reuters  ·  02-07
Recursion Pharmaceuticals Director Christopher Gibson Reports Sale of Common Shares
Recursion’s REC-4881 Cancer Trial Terminated: Reading the Signals for RXRX Investors
TIPRANKS  ·  02-07
Recursion’s REC-4881 Cancer Trial Terminated: Reading the Signals for RXRX Investors
The Genesis Mission Has a 270-Day Timeline – And You’re Already Late
InvestorPlace  ·  01-27
The Genesis Mission Has a 270-Day Timeline – And You’re Already Late
Is Recursion (RXRX) Turning Nvidia-Backed AI Hype Into a Durable Drug Discovery Advantage?
Simply Wall St.  ·  01-23
Is Recursion (RXRX) Turning Nvidia-Backed AI Hype Into a Durable Drug Discovery Advantage?
Director Christopher Gibson Sells Common Shares of Recursion Pharmaceuticals Inc
Reuters  ·  01-23
Director Christopher Gibson Sells Common Shares of Recursion Pharmaceuticals Inc
Is It Time To Reassess Recursion Pharmaceuticals (RXRX) After Recent Share Price Weakness
Simply Wall St.  ·  01-17
Is It Time To Reassess Recursion Pharmaceuticals (RXRX) After Recent Share Price Weakness
Nvidia Concept Stocks Rally. CoreWeave Up 8%; Recursion Up 4%; Nebius Up 3%; WeRide And Applied Digital Up 2%; SoundHound Up 1%
Tiger Newspress  ·  01-12
Nvidia Concept Stocks Rally. CoreWeave Up 8%; Recursion Up 4%; Nebius Up 3%; WeRide And Applied Digital Up 2%; SoundHound Up 1%
Recursion Updates AI Drug Platform, Financial Outlook at JPM
TIPRANKS  ·  01-12
Recursion Updates AI Drug Platform, Financial Outlook at JPM
Recursion Pharmaceuticals Files Initial Beneficial Ownership Statement for CSO David Hallett
Reuters  ·  01-10
Recursion Pharmaceuticals Files Initial Beneficial Ownership Statement for CSO David Hallett
Recursion Pharmaceuticals Director Christopher Gibson Reports Sale of Common Shares
Reuters  ·  01-08
Recursion Pharmaceuticals Director Christopher Gibson Reports Sale of Common Shares
Recursion Pharmaceuticals (RXRX): Assessing Valuation After New Activist Investor Filings With the SEC
Simply Wall St.  ·  01-05
Recursion Pharmaceuticals (RXRX): Assessing Valuation After New Activist Investor Filings With the SEC
Getty Images, Torm, and More Stocks See Action From Activist Investors -- Barrons.com
Dow Jones  ·  01-03
Getty Images, Torm, and More Stocks See Action From Activist Investors -- Barrons.com
Recursion CFO Ben R. Taylor Reports Sale of Common Shares
Reuters  ·  2025-12-31
Recursion CFO Ben R. Taylor Reports Sale of Common Shares
Chief R&D Commercial Officer Najat Khan Sells Recursion Pharmaceuticals Common Shares
Reuters  ·  2025-12-30
Chief R&D Commercial Officer Najat Khan Sells Recursion Pharmaceuticals Common Shares
3 Small AI Plays to Buy for 2026
Benzinga_recent_news  ·  2025-12-27
3 Small AI Plays to Buy for 2026
Recursion Pharmaceuticals CEO Christopher Gibson Reports Sale of Common Shares
Reuters  ·  2025-12-20
Recursion Pharmaceuticals CEO Christopher Gibson Reports Sale of Common Shares
Recursion Pharmaceuticals (RXRX): Valuation Check After Encouraging TUPELO Trial Data and Analyst Upgrades
Simply Wall St.  ·  2025-12-19
Recursion Pharmaceuticals (RXRX): Valuation Check After Encouraging TUPELO Trial Data and Analyst Upgrades

Introduction

Company Name.
Recursion Pharmaceuticals, Inc.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 1b/2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer; REC-64151 for the treatment of immune checkpoint resistance; and Anti-PD-(L)1, an orally bioavailable small molecule to improve sensitivity to immune checkpoint inhibitors in non-small cell lung cancer and additional tumors. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Chromaderm, Inc.; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.
Issue price:
--